SCHEMBL20920185

SCHEMBL20920185

Fc1ccc(CN2CN=C(SCc3ccccc3CSC3=NCN(Cc4ccc(F)c(Cl)c4)CN3)NC2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.42
▸ CYP2D6 P10635 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ KMT2A Q03164 5/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HIF1A Q16665 1/20 0.39
▸ DRD4 P21917 1/20 0.37
▸ SOS1 Q07889 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ GFER P55789 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ P2RX7 Q99572 2/20 0.35
▸ TRAP1 Q12931 2/20 0.35
▸ DAO P14920 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22263088 0.92 CYP1A2 (0.42) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL20917965 0.91 MAPK1 (0.41) CYP1A2CYP2D6TSHRKMT2AHIF1A
SCHEMBL22275605 0.91 CYP1A2 (0.38) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL22263126 0.90 HTT (0.41) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL20920814 0.89 SOS1 (0.39) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL20918028 0.87 CYP1A2 (0.44) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL22263137 0.84 MAPK1 (0.50) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL22263119 0.83 ALDH1A1 (0.43) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL20920834 0.83 CYP1A2 (0.51) CYP1A2CYP2D6TSHRKMT2ALMNA
SCHEMBL20917818 0.81 KMT2A (0.46) CYP1A2CYP2D6TSHRKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092020-A1 IDO/TDO Inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-03-20 — — US disclosed
US-12209079-B2 IDO/TDO inhibitor GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2025-01-28 — — US disclosed
US-20220380305-A1 IDO/TDO Inhibitor CANBAS CO., LTD. 2022-12-01 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed
US-20200239452-A1 IDO/TDO Inhibitor CANBAS CO., LTD. (JP) 2020-07-30 — — US disclosed
WO-2019078246-A1 IDO/TDO INHIBITOR 一般社団法人ファルマバレープロジェクト支援機構 2019-04-25 — — WO disclosed
WO-2019078246-A1 IDO/TDO INHIBITOR 一般社団法人ファルマバレープロジェクト支援機構 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209079-B2 IDO/TDO inhibitor IDO1, IDO2, TDO2 CYP1A2 363/4885CYP2D6 575/4885TSHR 115/4885
US-20200239452-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 CYP1A2 363/4885CYP2D6 575/4885TSHR 115/4885
US-20250092020-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 CYP1A2 363/4885CYP2D6 575/4885TSHR 115/4885
US-20220380305-A1 IDO/TDO Inhibitor IDO1, IDO2, TDO2 CYP1A2 508/4885CYP2D6 948/4885TSHR 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback